Literature DB >> 18852580

Preoperative angiotensin-converting enzyme inhibitors protect myocardium from ischemia during coronary artery bypass graft surgery.

Umberto Benedetto1, Giovanni Melina, Fabio Capuano, Cosimo Comito, Roberto Bianchini, Caterina Simon, Simone Refice, Emiliano Angeloni, Riccardo Sinatra.   

Abstract

OBJECTIVES: Coronary artery bypass graft surgery may result in perioperative myocardial injury during cardioplegic arrest. Angiotensin-converting enzyme (ACE) inhibitors protect the myocardium from ischemia in several clinical conditions, but no previous study has attempted to evaluate the impact of preoperative ACE inhibitor therapy on myocardial protection in patients undergoing coronary artery bypass graft surgery.
METHODS: A propensity score-based analysis of 481 patients undergoing isolated on-pump coronary artery bypass graft surgery was carried out, among which 245 patients received preoperative ACE inhibitors and 236 patients did not. Perioperative myocardial injury was assessed by ischemia marker cardiac troponin I (cTnI).
RESULTS: Preoperative cTnI concentration was similar for patients receiving ACE inhibitors and those who did not [0.1 ng/ml (0.06-0.19) versus 0.1 ng/ml (0.06-0.19); P = 0.3]. Postoperative cTnI peak concentration was lower in patients receiving preoperative ACE inhibitors [1.6 ng/ml (1.05-3.4) versus 2.4 ng/ml (1.13-6.10); P = 0.0006]. After adjusting for propensity score and covariates, preoperative ACE inhibitors were found to decrease postoperative cTnI peak concentration (beta = -0.12; P = 0.004). Other independent predictors of postoperative cTnI peak concentration were female gender, emergency surgery, number of distal anastomoses and aortic cross clamp time. Overall, operative mortality rate was 16/481 (3.3%). Patients receiving preoperative ACE inhibitors had a lower rate of postoperative myocardial infarction (2.0 versus 4.2%; P = 0.25) and low cardiac output syndrome (3.6 versus 6.3%; P = 0.24).
CONCLUSION: ACE inhibitors prior to surgery confer added myocardial protection during surgical revascularization. Prospective, randomized clinical trials will be necessary to better define the role of ACE inhibitors in improving outcomes when they are prescribed prior to coronary artery bypass graft surgery.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18852580     DOI: 10.2459/JCM.0b013e32830a6daf

Source DB:  PubMed          Journal:  J Cardiovasc Med (Hagerstown)        ISSN: 1558-2027            Impact factor:   2.160


  7 in total

1.  Angiotensin Receptor Blockade Improves Cardiac Surgical Outcomes in Patients With Metabolic Syndrome.

Authors:  Michael W Manning; Mary Cooter; Joseph Mathew; John Alexander; Eric Peterson; T Bruce Ferguson; Renato Lopes; Mihai Podgoreanu
Journal:  Ann Thorac Surg       Date:  2017-01-25       Impact factor: 4.330

2.  A patient with AKI after cardiac surgery.

Authors:  Ashita J Tolwani
Journal:  Clin J Am Soc Nephrol       Date:  2014-03-20       Impact factor: 8.237

Review 3.  Extracellular signalling molecules in the ischaemic/reperfused heart - druggable and translatable for cardioprotection?

Authors:  P Kleinbongard; G Heusch
Journal:  Br J Pharmacol       Date:  2014-11-24       Impact factor: 8.739

Review 4.  Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.

Authors:  Zui Zou; Hong B Yuan; Bo Yang; Fengying Xu; Xiao Y Chen; Guan J Liu; Xue Y Shi
Journal:  Cochrane Database Syst Rev       Date:  2016-01-27

5.  Effects of 60 minutes of hyperoxia followed by normoxia before coronary artery bypass grafting on the inflammatory response profile and myocardial injury.

Authors:  Inga Karu; Peeter Tähepõld; Arno Ruusalepp; Kersti Zilmer; Mihkel Zilmer; Joel Starkopf
Journal:  J Negat Results Biomed       Date:  2012-09-14

6.  The Hypertension Paradox: Survival Benefit After ST-Elevation Myocardial Infarction in Patients With History of Hypertension. A Prospective Cohort- and Risk-Analysis.

Authors:  Fabian Hoffmann; Patricia Fassbender; Wilhelm Zander; Lisa Ulbrich; Kathrin Kuhr; Christoph Adler; Marcel Halbach; Hannes Reuter
Journal:  Front Cardiovasc Med       Date:  2022-02-24

7.  Comparison of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Management Strategies Before Cardiac Surgery: A Pilot Randomized Controlled Registry Trial.

Authors:  Sean van Diepen; Colleen M Norris; Yinggan Zheng; Jayan Nagendran; Michelle M Graham; Damaris Gaete Ortega; Derek R Townsend; Justin A Ezekowitz; Sean M Bagshaw
Journal:  J Am Heart Assoc       Date:  2018-10-16       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.